Diabetes is prevalent in obese population, and obesity management is the first step in preventing diabetes. Traditionally, lifestyle modification including reduced-calorie diet, physical activity, and behavior intervention is the core of obesity management. However, pharmacotherapy is frequently required in addition to the lifestyle modification for effective reduction of body weight. There are five classes of anti-obesity medications approved by the U.S. Food and Drug Administration for chronic treatment used in obesity management. As the goal of obesity management is to prevent obesity-related comorbidities, clinical trials were conducted to evaluate the effect of anti-obesity medications on cardiovascular risk factors including hyperglycemia. Orlistat and liraglutide have been tested for their effect on diabetes prevention as a primary outcome. Cardiovascular safety studies were conducted for lorcaserin and liraglutide (as an anti-diabetic medication). In addition, there are many indirect evidences of the role of anti-obesity medications on diabetes prevention and its microvascular and macrovascular complications. This review focused on current evidences of anti-obesity medications related with diabetes, which is a major complication of obesity. chronic treatment. These are orlistat, lorcaserin, phentermine/topiramate extended-release (ER), naltrexone sustained release (SR)/ bupropion SR, and liraglutide 3.0 mg. In this review, I focused on the evidence and mechanistic explanation of each drug in preventing diabetes and its complications.
INTRODUCTION
The prevalence of obesity has doubled since 1980 and this trend has continued over time. 1 This is a serious global health problem and we need appropriate prevention strategies for obesity itself and obesity related comorbidities. Diabetes is the most hazardous obesity related comorbidity and it can be prevented by reducing body weight. 2, 3 Furthermore, for the individuals who already suffer from diabetes, a larger body weight reduction brought a better glucose control and health benefit on one year 4 and even longer term. 5 Reducing hyperglycemia is one of the most important prevention strategies for diabetes complications. 6, 7 Moreover, obesity management is important not only for the prevention of diabetes but also for the delay of diabetes related complications.
Life style modification including healthy meal plan, increase of physical activity, and behavior intervention is an essential part of obesity management. 8 However, majority of patients need pharmacotherapy to control their body weight effectively. Currently, there are five classes of pharmacotherapy for obesity, which have been approved by the U.S. Food and Drug Administration (FDA) for
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The Finnish Diabetes Prevention Study (DPS) and Diabetes
Prevention Program (DPP) demonstrated that intensive lifestyle modification reduced the incidence of diabetes by 58% compared to placebo during around 3 years. 9, 10 The study participants of DPS were given detailed advice to reduce their body weight by 5% or more including dietary advice and individual guidance for physical activity. 10 In DPP, subjects participated a 16-session one to one curriculum of diet, exercise, and behavioral modification to achieve the goal of body weight reduction (at least 7% of baseline body weight). 9 They were encouraged to follow healthy low calorie, lowfat diet and at least 150 minutes of moderate intensity exercise per week. At the end of study, the body weight loss from the baseline was 4.2 kg in DPS and 5.6 kg in DPP. Therefore, life style modification is generally recommended to prevent diabetes. However, the success of life style modification is hardly achieved without a supervised program. 11 Therefore, pharmacotherapy is necessary in many situations. Some of the anti-obesity medications were evaluated for their role in prevention of diabetes as a primary or secondary outcomes (Table 1) .
Orlistat
Orlistat was approved in 1999 by the FDA as an anti-obesity medication. Orlistat is a lipase inhibitor, which prevents the absorption of dietary fat. Moreover, it is the only peripheral acting antiobesity medication. 12 According to two phase III studies performed in European countries 13 and the USA, 14 it has been proved that orlistat promotes a significant weight loss and improves hyperglyce-mia in obese subjects. A pooled analysis 15 including these two studies showed that subjects with impaired glucose tolerance (IGT) less progressed to diabetes in orlistat group than the placebo group 
Phentermine/topiramate ER
Phentermine/topiramate ER is a single-pill combination of phentermine, sympathomimetic amine and topiramate, an antiepileptic drug. This drug was approved for anti-obesity medication in 2012. There were two large scale randomized double-blind, placebo-controlled studies to prove the efficacy of body weight reduction of phentermine/topiramate ER in overweight or obese subjects. 20, 21 However, there was no study to assess the prevention of Subgroup analysis including subjects with prediabetes and/or metabolic syndrome at baseline showed that the annual incidence rate of type 2 diabetes was 1.3 for high dose phentermine/topiramate and 6.1 in placebo. 23 The reduction rate is likely to be exaggerated in high risk subjects for diabetes. From the data of pooled analysis of phase III studies, only 24 were needed to be treated to prevent one event of new type 2 diabetes for 56 weeks in the highest risk group in contrast to the number needed to be treated increasing up to 120 in the lowest risk group. 24 In addition, greater body weight loss was associated with greater reduction in progression to type 2 diabetes. In this regard, it is necessary to find appropriate subjects to have good adherence to the medication in a longer term of use among subjects at having high risk of diabetes.
Lorcaserin
Lorcaserin is a 5-hyroxytryptamine receptor 2C agonist. This drug stimulates proopiomelanocortin (POMC) neurons in the hypothalamus and decreases appetite. 25 This drug was approved as an anti-obesity medication in 2012. Two phase III studies 26, 27 including overweight and obese subjects without diabetes and one phase III study 28 including those with diabetes were conducted and chronic treatment (1-year and 2-year) with lorcaserin reduced more body weight compared to placebo (5%-6% vs. 1%-2%). Af-ter these studies, CAMELLIA-TIMI 61 study was conducted independently to assess the cardiovascular safety and efficacy of lorcaserin. 29 Among the study population, the prespecified primary metabolic efficacy, which is evaluated as the time to incident type 2 diabetes, was analyzed in 3,991 subjects with prediabetes at baseline. 30 During a median follow-up of 3.3 years, lorcaserin reduced the risk of incidence of diabetes by 19% (HR, 0.81; 95% CI, 0.66-0.99). Furthermore, remission rate of hyperglycemia was higher in lorcaserin treatment than placebo in subjects with type 2 diabetes at baseline (HR, 1.21; 95% CI, 1.07-1.36). 30 Interestingly, glycosylated hemoglobin (HbA1c) reduction occurred earlier than significant weight loss. From a preclinical study, lorcaserin suppressed hepatic glucose production via melanocortin 4 receptor signaling, which phenomenon was independent to its anorectic effect. 31 Therefore, lorcaserin might have direct mechanism to reduce hyperglycemia in improving insulin sensitivity.
Naltrexone SR/bupropion SR
Naltrexone blocks the opioid-mediated POMC auto-inhibition and bupropion stimulates the hypothalamic POMC neuron. Combination of these two drugs showed synergistic effects in body weight reduction, 32 and was approved as an anti-obesity medication in 2014.
There were four Contrave Obesity Research (COR) studies. The COR-I, 33 COR-II, 34 and COR-behavior modification 35 included subjects without diabetes. Among these studies, only COR-I study showed a significant decrease of fasting plasma glucose in naltrexone SR 32 mg/bupropion SR 16 mg combination treatment, but all three of the studies did not evaluate the incidence of diabetes.
According to COR-Diabetes study 36 including subjects with type 2 diabetes under lifestyle modification and/or oral antidiabetic medications, HbA1c levels decreased more in naltrexone SR/bupropion SR combination treatment than in placebo after 1-year (-0.6% vs.
-0.1%, P< 0.001). However, there was no data about the remission rate of diabetes. Further longer-term study will be necessary to establish the effect of this medication on diabetes prevention. In summary, even though it exhibited comparable effects on body weight reduction when it was indirectly compared to other anti-obesity medication, there is very limited data of naltrexone SR/bupropion SR combination treatment for its effect on diabetes prevention. 37 Oh TJ Anti- 
Liraglutide
Liraglutide is a GLP-1 receptor agonist and it has been first approved as an anti-diabetic medication. 38 Higher dose of liraglutide (3.0 mg per day) showed greater body weight loss in a phase 2 study and the magnitude of body weight reduction was greater than orlistat. 39 Following the SCALE study, a large scaled randomized double-blind, placebo-controlled study, confirmed that 3.0 mg of liraglutide effectively reduced body weight compared to the placebo (a difference of -5.6 kg; 95% CI, -6.0 to -5.1 kg; P < 0.001). 40 Subjects with prediabetes at baseline (n = 2,254) continued on liraglutide 3.0 mg or placebo for 2 more years. 41 The risk of diabetes was much lower in liraglutide group than the placebo group (HR, 0.21;
95% CI, 0.13-0.34; P < 0.001). This significant difference remained after a 12-week follow-up after discontinuation of treatment. In this period, decrease of insulin resistance was maintained.
Furthermore, liraglutide induced more regression from prediabetes to normoglycemia than placebo (odds ratio, 3.6; 95% CI, 3.0-4.4;
P < 0.001). The amount of body weight reduction in those with newly developed diabetes was less than those who were not diagnosed with diabetes in each treatment group, which might implicate that body weight reduction play a primary role in delay of diabetes. Therefore, body weight reduction might have a primary role in delay of diabetes. In addition, GLP-1 showed a beta-cell preservation effect in preclinical 42 and clinical studies. 43, 44 Taken together, chronic treatment with liraglutide might improve both beta-cell function and insulin sensitivity followed by body weight reduction and finally prevent diabetes in high risk patients.
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Not only intensive glycemic control 45 but also effective management of high blood pressure and dyslipidemia 46 can reduce the risk of chronic diabetic complications. Therefore, anti-obesity medications have a potential role in delaying the diabetes related complications ( Fig. 1) . Figure 1 . The role of anti-obesity medications on diabetes complication risk management. Data from XENDOS (orlistat), 16 CONQUER (phentermine/topiramate extendedrelease [ER]), 20 BLOOM (lorcaserin), 26 COR (naltrexone SR/bupropion SR), 33 and SCALE (liraglutide). 40 ER, extended-release; SR, sustained release; PP2, postprandial 2 hourplasma glucose; FPG, fasting plasma glucose; SBP, systolic blood pressure; TC, total cholesterol; TG, triglyceride; XENDOS, Xenical in the Prevention of Diabetes in Obese Subjects; COR, Contrave Obesity Research.
Orlistat
Cardiovascular risk factors were assessed after a 1-year treatment of orlistat in subjects with diabetes. 50 Total and low-density lipoprotein cholesterol, and systolic blood pressure were significantly reduced in orlistat group than the placebo group. 47 In this study, 24-hour urine albumin excretion was also significantly decreased after orlistat treatment (Table 2) . Therefore, orlistat induced weight reduction effectively and also controlled cardiovascular risk factors. However, there was no large scale randomized controlled trial to evaluate the major adverse cardiovascular events (MACE).
Phentermine/topiramate ER
A retrospective study comparing MACE among phentermine/ topiramate ER fixed dose combination, each component use, and unexposed to each drug demonstrated that phentermine/topiramate ER did not increase MACE. 24 However, there was no study to demonstrate the effect of drug on diabetic microvascular and macrovascular complications.
Lorcaserin
In CAMELLIA-TIMI 61 study microvascular composite outcome ( 
Liraglutide
Liraglutide was firstly developed as anti-diabetic medication, and its cardiovascular safety data has been published. 52 This analysis showed a broad range of CI because SCALE study enrolled subjects with relatively low cardiovascular risk compared to subjects enrolled in LEADER study. According to the available data, liraglutide as an anti-obesity medication at least did not increase cardiovascular events in long term use. Furthermore, prespecified secondary renal outcomes in LEADER trial were less de- tected in liraglutide than placebo (HR, 0.78; 95% CI, 0.67-0.92), 49 in which the results were mainly derived by reducing albuminuria (Table 2) . Likewise, the higher dose regimen of liraglutide has not been studied, whether it reduces diabetic complications as prespecified outcomes.
CONCLUSION
Since obesity is the most important risk factor for type 2 diabetes, many anti-obesity medications have been tested for their role in diabetes prevention. In addition, the effect of anti-obesity medications on diabetes related complications have been demonstrated.
Many of them showed neutral effect on cardiovascular events.
However, further large scale long term studies should be performed to prove their roles in cardiovascular disease and microvascular complications as well.
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